RADIOPHARM THERANOSTICS LTD
RADXNASDAQTrading Snapshot
- Day Range
- $2.76 – $2.80
- 52-Week Range
- —
- Volume
- $5.48B
- Avg Volume
- $4.75B
- Shares Outstanding
- 3.93B
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 14.3x
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own RADX
- ✓High-growth profile — revenue up +55.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About RADIOPHARM THERANOSTICS LTD
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
RADX: RAD101 Topline & FY:26 Cash Flows
By John Vandermosten, CFA NASDAQ: RADX READ THE FULL RADX RESEARCH REPORT Fiscal 2026 Activity and Cash Flows Radiopharm Theranostics (NASDAQ: RADX) released its Quarterly Activities and Cash Report for its fourth quarter and fiscal year ending June 30 th , 2026. Beyond the review of cash sources and uses for the fiscal year 2026, the report highlighted recent clinical trial achievements for
Radiopharm Theranostics Reports Business Update
Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpoint Plans to initiate Phase 3 registrational trial of RAD 101 in Q4 2026 Raised approximately $12.5M through an institutional offer and launched a $6million Share Purchase Plan, post balance date SYDNEY, July 31, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stag
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday's pre-market session. The company's market cap stands at $1.4 million. OneMedNet (NASDAQ:ONMD) shares moved
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares increased by
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular session. The market value of their outstanding shares is at $17.4 billion. The company's, Q2 earnings came out